Table 1. PDX characterization based on BCa subtype (intrinsic subtype is presented in brackets).
| PDX | Subtype | PML |
|---|---|---|
| 31 | TNBC (HER2 enriched) | − |
| 102 | ER+ (basal like) | − |
| 131 | ER+ (luminal B) | − |
| 156 | ER+ (basal like) | − |
| 197 | TNBC (basal like) | − |
| 4 | ER+ (luminal B) | + |
| 6 | ER+ (luminal A) | + |
| 10 | HER2+ (HER2 enriched) | + |
| 39 | ER+ (luminal B) | + |
| 60 | ER+ (basal like) | + |
| 98 | ER+ (basal like) | + |
| 136 | TNBC (basal like) | + |
| 137 | TNBC (basal like) | + |
| 161 | ER+ (luminal B) | + |
| 93 | TNBC (NA) | ++ |
| 179 | TNBC (NA) | ++ |
| 44 | TNBC (basal like) | +++ |
| 88 | TNBC (basal like) | +++ |
| 89 | TNBC (NA) | +++ |
| 94 | TNBC (basal like) | +++ |
| 124 | TNBC (basal like) | +++ |
| 127 | TNBC (basal like) | +++ |
| 167 | TNBC (basal like) | +++ |
ER, oestrogen receptor; NA, not applicable; TNBC, triple-negative breast cancer.